Ituran Location and Control Ltd. announced record second-quarter 2026 revenue of $104.8 million, a 21% increase year-over-year, driven by a 25% rise in subscription revenue. Net income grew 29% to $17.3 million, and EBITDA increased 24% to $28.5 million, reflecting strong operating leverage. The company added 41,000 net subscribers, reaching 2.71 million, with growth across Israel and Latin America supported by OEM partnerships and new initiatives like IturanMob in the US. Ituran declared a $10 million dividend and continues to invest in growth areas, confident in sustained profitability for 2026.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
